MNTA—Phase-2 portion of Necuparanib trial in pancreatic cancer is powered at 80% to show a 50% increase in OS vs control arm of Gemzar + Abraxane. (Source: today’s R&D Day webcast)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.